These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 22755427)

  • 1. Summarizing the use of donor specific anti-HLA antibody monitoring in transplant patients.
    Everly MJ
    Clin Transpl; 2011; ():333-6. PubMed ID: 22755427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-specific anti-HLA antibody monitoring and removal in solid organ transplant recipients.
    Everly MJ
    Clin Transpl; 2011; ():319-25. PubMed ID: 22755425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A report of the epidemiology of de novo donor-specific anti-HLA antibodies (DSA) in "low-risk" renal transplant recipients.
    Rebellato LM; Everly MJ; Haisch CE; Ozawa M; Briley KP; Parker K; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC
    Clin Transpl; 2011; ():337-40. PubMed ID: 22755428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience.
    Leone JP; Bowers V; Baliga R; Sanders C; LeFor W; Becker D; Thompson D; Resto-Ruiz S; Lopez-Cepero M
    Clin Transpl; 2011; ():373-9. PubMed ID: 22755434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Annual literature review of donor-specific HLA antibodies after organ transplantation.
    Kaneku H
    Clin Transpl; 2011; ():311-8. PubMed ID: 22755424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
    Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
    Cooper JE; Gralla J; Chan L; Wiseman AC
    Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the significance of low-level preformed donor-specific anti-HLA antibodies in renal transplant patients.
    Wu P; Everly MJ; Jin J; Mao Y; Chen J
    Clin Transpl; 2011; ():365-8. PubMed ID: 22755432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted monitoring of donor-specific HLA antibodies following renal transplantation.
    Almeshari K; Pall A; Chaballout A; Elgamal H; Almana H; Alzayer F; Abaalkhail N; Altalhi M
    Clin Transpl; 2011; ():395-400. PubMed ID: 22755437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term post transplant alloantibody monitoring: a single center experience.
    Ntokou IS; Boletis JN; Apostolaki M; Vrani V; Zavos G; Kostakis A; Iniotaki A
    Clin Transpl; 2011; ():341-50. PubMed ID: 22755429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel post-transplant alloantibody surveillance and intervention strategy that improves graft outcomes in sensitized renal transplant recipients.
    Kimball PM; King A
    Clin Transpl; 2011; ():369-72. PubMed ID: 22755433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Monitoring of Donor-specific Anti-HLA Antibodies After Intestine/Multivisceral Transplantation: Significance of De Novo Antibodies.
    Kubal C; Mangus R; Saxena R; Lobashevsky A; Higgins N; Fridell J; Tector AJ
    Transplantation; 2015 Aug; 99(8):e49-56. PubMed ID: 25769071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using HLA antibody detection, monitoring, and treatment to improve long-term allograft survival.
    Everly MJ
    Clin Transpl; 2010; ():317-22. PubMed ID: 21696049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Donor-Specific Antibodies in Intestinal Transplantation: Experience at the University of California Los Angeles and Literature Review.
    Cheng EY; Kaneku H; Farmer DG
    Clin Transpl; 2014; ():153-9. PubMed ID: 26281140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging role of donor-specific anti-human leukocyte antigen antibody determination for clinical management after solid organ transplantation.
    Zeevi A; Lunz JG; Shapiro R; Randhawa P; Mazariegos G; Webber S; Girnita A
    Hum Immunol; 2009 Aug; 70(8):645-50. PubMed ID: 19527760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
    Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
    Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor-specific HLA antibodies: risk factors and outcomes after kidney transplantation.
    Kanter Berga J; Pallardo Mateu LM; Beltran Catalan S; Puig Alcaraz N; Sancho Calabuig A; Gavela Martinez E; Avila Bernabeu A; Crespo Albiach J
    Transplant Proc; 2011; 43(6):2154-6. PubMed ID: 21839219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantifying HLA-specific antibodies in patients undergoing desensitization.
    Zachary A; Reinsmoen NL
    Curr Opin Organ Transplant; 2011 Aug; 16(4):410-5. PubMed ID: 21666475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients.
    Cheng EY; Everly MJ; Kaneku H; Banuelos N; Wozniak LJ; Venick RS; Marcus EA; McDiarmid SV; Busuttil RW; Terasaki PI; Farmer DG
    Transplantation; 2017 Apr; 101(4):873-882. PubMed ID: 27490417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.